25 results about "Inflammatory cell infiltration" patented technology

The application discloses application of a PRMT3 inhibitor SGC707 in preparation of a drug for treating pulmonary fibrosis, and for the first time verifies that a selective PRMT3 inhibitor SGC707 can dose-dependently inhibit expression of fibrosis markers such as COL1A1 and alpha-SMA in fibroblasts induced by TGF-beta 1 in vitro; in a bleomycin (BLM) induced mouse pulmonary fibrosis model, SGC707 administration can significantly improve lung tissue collagen deposition, reduce inflammatory cell infiltration, repair alveolar structure damage, and effectively down-regulate expression levels of fibrosis related proteins in lung tissues. It is proved that PRMT3 is a functional target with important intervention value in pulmonary fibrosis, SGC707 has definite anti-pulmonary fibrosis activity in vitro and in vivo, and a new drug strategy is provided for treatment of pulmonary fibrosis.

The application discloses a kind of treatment granulomatous lobular mastitis plaster and preparation method thereof, it is related to traditional Chinese medicine technical field, and its technical solution points are: rhubarb, golden poplar, radix scutellariae, sanguisorba officinalis, gardenia, turmeric, purple grass, water decoct 2 times, first time 9-11 times water amount of medicinal materials is added, decoct 1-3 hours, second time 6-9 times water amount of medicinal materials is added, decoct 1-2 hours, two water decocting liquids are combined, after filtration, concentrate and obtain ointment, carry out coating, cut according to specification and place to make it solidification and shape.The application can realize the treatment granulomatous lobular mastitis, can reduce mastitis inflammation index score and inflammatory cell infiltration degree, by reducing the expression of IL6, CD86, TYROBP, ITGAX and regulating related path, play the role of treatment granulomatous lobular mastitis.

The application discloses a new use of a BET inhibitor YD-851 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis. The application finds that YD-851 can inhibit the expression of BRD4 and fibrosis-related markers in pulmonary fibrosis tissues, reduce the structural damage of bleomycin-induced mouse lung tissues, inflammatory cell infiltration and fibrosis pathological changes, and improve lung function damage. Experimental results show that YD-851 can reduce the pulmonary fibrosis score, inflammation score and area ratio of consolidation, improve the lung imaging abnormalities, and down-regulate the expression of fibrosis-related genes such as Col1a1, Fn1 and Acta2. It is shown that YD-851 has the effect of treating pulmonary fibrosis, and can be used for preparing a drug for treating pulmonary fibrosis, and a new use of YD-851 is developed.

The present application relates to a new use of halogenophenol compound 4,5,2'-trihydroxy-2,5'-dibromobenzophenone, in particular in the preparation of a drug for treating inflammatory bowel disease. The halogenophenol compound of the present application can significantly alleviate the weight loss and colon shortening of the colonitis model, reduce the disease activity index of the colonitis model, reduce the inflammatory cell infiltration of the colonitis model, reduce the expression of inflammatory factors, has an immune regulation function on the intestinal tract, and is superior to the clinical first-line drug mesalazine in most indicators, and has application prospects in the treatment of inflammatory bowel disease.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

This application proposes a traditional Chinese medicine composition and preparation method for treating atrophic gastritis of spleen deficiency and blood stasis type, involving the field of traditional Chinese medicine. It utilizes Bupleurum chinense, stir-fried Paeonia lactiflora, Citrus reticulata peel, Pinellia ternata, Codonopsis pilosula, Poria cocos, stir-fried Atractylodes macrocephala, prepared Glycyrrhiza uralensis, Agrimonia pilosa, and Curcuma zedoaria, and establishes a water extraction and decoction preparation process. A rat model of precancerous gastric lesions was established using MNNG combined with multiple factors. Normal control group, model group, folic acid group, and traditional Chinese medicine group were set up to observe the morphological and pathological changes of the gastric mucosa. The results showed that the traditional Chinese medicine composition can reduce gastric mucosal atrophy, inflammatory cell infiltration, and fibrous tissue hyperplasia, alleviate intestinal metaplasia, downregulate the expression of AKT and mTOR proteins in the gastric mucosa, and inhibit abnormal mucosal proliferation. Its effect is superior to that of folic acid, providing experimental evidence for clinical treatment.

This invention discloses Lactobacillus plantarum ( Lactobacillus plants The application of Lactobacillus plantarum AY01 in the preparation of products inhibiting colorectal cancer liver metastasis is described. The Lactobacillus plantarum AY01 is deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC M 20221517. The advantages of this invention are: Lactobacillus plantarum AY01 has the characteristics of inhibiting CT26.WT cell viability, suppressing CT26.WT cell clone formation, inhibiting CT26.WT cell scratch repair, reducing its migration ability, and thus reducing tumor metastatic potential. Mouse experiments with colorectal cancer liver metastasis show that the bacterial suspension of this strain can significantly reduce the number of tumors at metastatic sites in the liver, inhibit liver tumor colonization and proliferation, reduce inflammatory cell infiltration, reduce the proportion of Ki-67 and PCNA positive cells in the liver, alleviate liver tissue damage caused by colorectal cancer liver metastasis, promote the restoration of normal liver structure, protect the liver, and exert an anti-colorectal cancer liver metastasis effect, providing theoretical support for probiotic adjuvant therapy for colorectal cancer liver metastasis.

The application discloses a method for improving the anti-cellular fibrosis of intestinal flora based on polysaccharides, and the steps of the method include: preparing Yunnan rhizoma polygonati mutant polysaccharide PKVP-1; and placing the Yunnan rhizoma polygonati mutant polysaccharide PKVP-1 in an intestinal environment to improve the anti-cellular fibrosis of intestinal flora. The steps of an experimental method for improving the anti-cellular fibrosis of intestinal flora based on polysaccharides include: selecting experimental animals and performing random grouping, and then performing drug administration; collecting the intestinal contents and kidney tissues of the experimental animals; taking the kidney tissues of the experimental animals to prepare paraffin sections for trichrome staining, and evaluating the inflammation degree of the kidney tissues according to the inflammatory cell infiltration; performing sequencing; detecting metabolites and obtaining a conclusion according to metabolite analysis. The method for improving the anti-cellular fibrosis of intestinal flora based on polysaccharides provided by the application improves the anti-cellular fibrosis ability of intestinal flora by placing the mutant polysaccharide in the intestinal environment of the experimental animals.

The application belongs to the technical field of biological medicine, and particularly relates to a binding molecule targeting CCL5 and application of the binding molecule in combination with drugs in treatment of Th2-type inflammation related diseases. The application discloses use of a binding molecule targeting CCL5 or a pharmaceutical composition comprising the binding molecule in preparation of a product having one or more of the following functions: 1) prevention and / or treatment of Th2-type inflammation related diseases; 2) reduction of skin lesion tissue thickness; 3) reduction of clinical score of atopic dermatitis; 4) reduction of scratching behavior; 5) reduction of tissue damage; 6) alleviation of inflammatory reaction and inhibition of expression of inflammatory factors; and 7) reduction of inflammatory cell infiltration. The binding molecule targeting CCL5 or the pharmaceutical composition comprising the binding molecule has important value in prevention and treatment of immune inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy or drug allergy.

This application provides a hUC-MSC cell suspension formulation for treating allergic rhinitis and its preparation method. It comprises mammalian stem cells, a pharmaceutically acceptable suspension carrier, and a protective agent. The mammalian stem cells are mesenchymal stem cells, which can be derived from the human umbilical cord. The formulation is suitable for intravenous administration. The preparation method includes: washing the resuscitated stem cells with phosphate buffer, centrifuging, resuspending them in a suspension carrier, adding the suspension carrier and protective agent, and mixing thoroughly. Experiments show that this formulation can reduce the levels of interleukin-4 and interleukin-5 in the serum and spleen of mice with allergic rhinitis, and alleviate inflammatory cell infiltration in the nasal mucosa.

The application discloses a multifunctional piezoelectric and immune-regulating PG@ZnO composite fiber membrane, a preparation method and application thereof, and belongs to the field of biological medicines.The PG@ZnO composite fiber membrane comprises a PG fiber membrane composed of left-handed polylactic acid (PLLA) and gelatin and ZnO nanoparticles distributed on the surface and inside the fibers of the PG fiber membrane.Based on the piezoelectric characteristics of PLLA and the antibacterial and immune-regulating functions of the ZnO nanoparticles, the application constructs a PG@ZnO composite fiber membrane which has mechanical support, piezoelectric response and immune microenvironment regulation functions.The composite fiber membrane is used in pelvic floor repair, has good biocompatibility, can effectively promote HUVECs to form tubes and can induce macrophages to polarize to M2 type.In a rat abdominal wall muscle defect model, the PG@ZnO composite fiber membrane significantly inhibits inflammatory cell infiltration, promotes collagen ordered deposition and angiogenesis and accelerates functional regeneration of tissues.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

The application relates to application of cedrene diol in preparation of medicines for preventing and treating rosacea, and belongs to the technical field of biological medicines. The application provides application of cedrene diol in preparation of medicines for preventing and / or treating rosacea. The cedrene diol can significantly improve redness and inflammation of an injection area of a rosacea mouse model in long and short terms, can significantly relieve skin histopathological inflammation of the rosacea mouse model (including improving thickening of skin epidermis of the rosacea mouse model, reducing inflammatory cell infiltration of skin tissue of the rosacea mouse model, and reducing capillary proliferation of skin tissue of the rosacea mouse model), can significantly reduce skin inflammation of a rosacea patient (including reducing pain of the skin of the rosacea patient and relieving redness of the skin of the rosacea patient), and can significantly improve skin damage of the rosacea patient (including improving papules and pustules of the skin of the rosacea patient).

This invention belongs to the technical field of biomedicine and discloses the application of a composition comprising neo-agar oligosaccharides and astaxanthin in the preparation of formulations for the treatment of dry eye syndrome, as well as the formulation of in-situ gel eye drops and its preparation method. The composition provided by this invention specifically comprises neo-agar oligosaccharides and astaxanthin, which together constitute an organic whole, synergistically contributing to excellent ocular surface retention time and penetration efficiency. It can effectively inhibit the activation of core inflammatory pathways at low doses, reduce inflammatory cell infiltration in ocular surface tissues, promote goblet cell proliferation and epithelial repair, increase tear secretion, and improve corneal epithelial integrity. This achieves multiple effects, including anti-inflammatory properties, increased tear secretion, reduced corneal damage, promotion of ocular surface tissue repair, and improvement of corneal epithelial integrity. Furthermore, the composition exhibits excellent ocular surface biocompatibility and has very promising application prospects in the preparation of formulations for the treatment of dry eye syndrome.

The application provides a novel biphenyl compound and application thereof in preparation of a drug for treating pulmonary fibrosis, relates to the technical field of medicines, and the biphenyl compound is shown as general formula I. The compound can significantly improve BLM-induced pulmonary fibrosis in mice, and specific performance is as follows: reducing the range of pulmonary consolidation, repairing lung tissue structure, improving the survival rate of mice, reducing the lung coefficient, reducing pulmonary interstitial thickening, inflammatory cell infiltration and fibroblast focus formation, reducing abnormal deposition of collagen fibers in the pulmonary interstitium, and having a clear dose-effect relationship and good biological safety. The application provides a solid experimental basis for the application of the compound in preparation of the drug for treating pulmonary fibrosis, and has a wide application prospect.

This invention belongs to the field of traditional Chinese medicine preparation technology, and provides a traditional Chinese medicine composition with anti-inflammatory, swelling-reducing, analgesic, and joint-relieving properties, its preparation method, and its application in the preparation of drugs for treating arthralgia. The method includes the following steps: Smilax glabra, Corydalis yanhusuo (processed with vinegar), and Stephania tetrandra are pulverized, mixed, decocted with water, filtered, the filtrate is concentrated, ethanol is added to precipitate, the supernatant is collected, the ethanol is recovered and concentrated to obtain a water-extracted alcohol-immersed extract, which is then mixed with maltodextrin, wet-granulated, and dried to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition obtained by this invention is based on the principles of promoting joint mobility, reducing swelling and relieving pain. It can significantly inhibit ankle joint swelling in rats with gouty arthritis, improve local inflammatory cell infiltration, and reduce synovial tissue hyperplasia in rats with gouty arthritis.

The application discloses a composition for preventing and / or treating candidal vaginitis, and belongs to the field of medicine. It is found for the first time that a composition containing volatile oil of pachystachys jutna and total alkaloids of Sophora flavescens can significantly inhibit the adhesion and invasion ability of Candida albicans to VK2 / E6E7 cells. Meanwhile, in a mouse candidal vaginitis model, the composition can effectively reduce the vaginal fungal load of the mouse candidal vaginitis model, improve the pH value of vaginal secretion, and improve the inflammatory cell infiltration of the vaginal tissue, and has clinical popularization and application value.

This invention belongs to the field of biomedical technology and provides an application of a ferroptosis inhibitor in the treatment of hepatitis. This invention reveals that a GRIM-19 gene defect specifically induces ferroptosis in hepatocytes, rather than other cell death mechanisms such as apoptosis, necrosis, or autophagy. This invention provides a ferroptosis inhibitor with Ferrostatin-1 as the active ingredient, solving the technical problem of insufficient intervention against the ferroptosis mechanism in existing hepatitis treatments. This inhibitor can significantly increase the expression level of GPX4 in liver tissue, effectively clear lipid peroxides, a core toxic product in the ferroptosis process, and block the ferroptosis process; in addition, it can significantly inhibit the activation of the NLRP3 inflammasome and reduce the expression of downstream inflammatory factors, thereby alleviating inflammatory cell infiltration and fibrotic lesions in the liver. This invention is applicable to the treatment of GRIM-19 deficiency-related chronic hepatitis, providing a new strategy for targeted therapy of liver diseases.

The application discloses application of piRNA-AMIPIR in preparation of a drug for improving heart injury after acute myocardial infarction. The application first discovers that piRNA-AMIPIR is highly expressed in myocardial tissue after acute myocardial infarction (MI), and the expression level is positively correlated with the myocardial injury degree. After administration of the antisense nucleotide Antagomir-AMIPIR designed based on the piRNA-AMIPIR in a mouse acute myocardial infarction model, the myocardial cell apoptosis is reduced, the active oxygen (ROS) accumulation is reduced, the inflammatory cell infiltration is inhibited, the heart contraction function is significantly improved, and the ischemia-induced heart injury is reduced. The application confirms the potential value of the piRNA-AMIPIR as a treatment target for heart injury after acute myocardial infarction, the antisense nucleotide provides a new candidate drug and treatment strategy for clinical treatment of acute myocardial infarction, and has important scientific research significance and clinical application prospect.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of cinnabar extract in the preparation of drugs for the prevention and treatment of gastric ulcers. The preparation method of the extract is as follows: Cinnabar is extracted by reflux with a 60%–80% (v / v) ethanol solution. The extracts are combined, evaporated to dryness, and then mixed with water to obtain an extract. The extract is then diluted, adsorbed onto a macroporous resin, and eluted with a 35%–45% (v / v) ethanol solution. The eluent is then evaporated to dryness to obtain the final extract. Experiments show that this extract can significantly reduce gastric mucosal damage in mice, decrease the ulcer index, and increase the ulcer inhibition rate, with effects superior to the positive control drug ranitidine. Its mechanism of action includes reducing inflammatory cell infiltration, decreasing the content of pro-inflammatory factors, pepsin activity, and malondialdehyde content, and increasing antioxidant enzyme activity. This invention provides a new natural drug source for the treatment of gastric ulcers, with a clearly defined active pharmaceutical ingredient and promising clinical application prospects.

The application belongs to the technical field of biological medicine, and particularly relates to POFUT1 The application discloses an application of a gene function inhibitor in preparation of a drug for treating cholestatic liver disease. POFUT1 It is found for the first time that inhibition of the function of the gene can significantly reduce the degree of liver lesion of cholestatic liver disease. POFUT1 The deletion of the gene can significantly reduce serum liver enzyme, bile acid and bilirubin levels, reduce liver inflammatory cell infiltration and collagen deposition. Further verification by AAV8-mediated RNA interference technology shows that targeted silencing of the gene in liver cells can effectively alleviate liver injury and liver fibrosis. POFUT1 The application provides a novel treatment target and strategy for cholestatic liver disease, and has a wide clinical application prospect.

This invention discloses an inhibitor of lncRNA Rmst-3 and its application in the preparation of drugs for treating acute lung injury caused by bacterial infection. The study found that lncRNA Rmst-3 is significantly overexpressed in tissues with acute lung injury induced by Gram-negative bacterial infection; it specifically adsorbs miR-1958 as a competitive endogenous RNA, thereby relieving the inhibition of the target gene CD38, leading to activation of the downstream SIRT1 / NF-κB / NLRP3 signaling pathway, triggering macrophage pyroptosis and inflammatory storm. The Rmst-3 inhibitor or miR-1958 mimic provided by this invention can effectively block the above signaling axis, significantly reduce pulmonary edema, hemorrhage, and inflammatory cell infiltration, decrease the bacterial load in lung tissue, and improve the survival rate of individuals with acute lung injury. This invention reveals a new mechanism of ALI pathogenesis, providing new molecular targets and drug strategies for clinical treatment.

A traditional Chinese medicine composition for improving or treating acute lung injury and an application thereof. The traditional Chinese medicine composition is made of the following traditional Chinese medicine raw materials: Areca catechu 12-24 parts, Magnolia officinalis 6-12 parts, Amomum tsao-ko 3-6 parts, Anemarrhena asphodeloides 6-12 parts, Paeonia lactiflora 6-12 parts, Scutellaria baicalensis 6-12 parts, Glycyrrhiza uralensis 3-6 parts, Rheum officinale 6-12 parts, Forsythia suspensa 8-16 parts, Mentha haplocalyx 3-6 parts, Gardenia jasminoides 3-6 parts, Mirabilite 3-6 parts, and Bambusa 5-10 parts. In a mouse animal model experiment, the traditional Chinese medicine composition described herein not only can alleviate the phenomenon of inflammatory cell infiltration in the bronchoalveolar lavage fluid caused by LPS, reduce the inflammatory response, but also can help to improve the lung tissue pathological injury induced by LPS, maintain the alveolar structure integrity, inhibit pulmonary edema, down-regulate the level of inflammatory factors in the bronchoalveolar lavage fluid, and inhibit the expression of inflammatory factors in the lung tissue, thereby improving or treating acute lung injury caused by LPS.

Chronic inflammatory bowel disorders (IBDs) are characterized by altered intestinal permeability, prompting inflammatory, oxidative stress and immunological factors. Gut microbiota disorders impact brain function via the bidirectional gut-brain axis, influencing behavior through inflammatory cascades, oxidative stress, and neurotransmitter levels. The present invention comprises lyophilized milk kefir alone and lyophilized milk kefir as solid carriers loaded with self-nanoemulsifying self-nanosuspension (SNESNS) of licorice extract. Daily administration of lyophilized milk kefir loaded with SNESNS restores normal body weight and intestinal mucosa while significantly reducing submucosal inflammatory cell infiltration, leading to significant alleviation of neurotransmitter levels and improved memory functions, thereby addressing gut-brain axis disorders. Additionally, it normalized fecal microbiome constituents, inflammatory cytokine levels, and oxidative stress in examined tissues and serum. Moreover, daily administration of kefir-loaded SNESNS normalizes the disease activity index, alleviates histopathological changes induced by IBD induction, and partially restored the normal gut microbiota. These alterations are associated with improved cognitive functions, attributed to the maintenance of normal neurotransmitter levels and alleviation of triggered inflammatory factors and oxidative stress levels.